Isis Pharmaceuticals Earns $2 Million from GSK

barbara.lempert Isis Pharmaceuticals Earns $ 2 Million from GSK for the Advancement of ISIS-TTR Rx CARLSBAD, Calif., July 30, 2013 /PRNewswire/ — Isis Pharmaceuticals, ...

For Pharma CEO, A Smaller Pond, Bigger Waves

barbara.lempert PHILADELPHIA, July 29, 2013 (PHILADELPHIA INQUIRER)–Before Maxine Gowen left the pharmaceutical giant GlaxoSmithKline in 2007, she was one of 103,000 ...

McKesson Fights A Clawback Policy Proposed By Big Investors

esilverman Should one of the largest drug wholesalers have a clawback policy for executives? Two institutional investors believe the notion is overdue for McKesson, since the ...

Dr. Reddy’s Q1 FY14 Financial Results

barbara.lempert Q1 FY14 Revenues at Rs. 28.4 billion (YoY growth of 12%) Q1 FY14 EBITDA at Rs. 5.7 billion (20% of the revenues, with YoY growth of 13%) Q1 FY14 Adjusted PAT* ...

Depomed Acquires Archimedes’ Lazanda for $4M

barbara.lempert Depomed Announces Acquisition Of Lazanda® (fentanyl) Nasal Spray From Archimedes Pharma Limited NEWARK, Calif., July 29, 2013 /PRNewswire/ — Depomed, ...

New compound could combat castration-resistant prostate cancer

Emily Mullin Researchers at Sanford-Burnham Medical Research Institute may have hit on the next big thing in prostate cancer treatment. They've developed a compound called SMIP004 ...

New Data for Abbott’s Investigational High Sensitive Troponin Test

barbara.lempert New Data for Abbott’s Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk HOUSTON, July 30, 2013 /PRNewswire/ — ...

Cubist splurges on Trius and Optimer buyouts to spur antibiotics growth

Ryan McBride Cubist Pharmaceuticals surprised some analysts with the announcements of two major acquisitions Tuesday afternoon, agreeing to buy both Trius Therapeutics and Optimer Pharmaceuticals ...

Amgen: 2Q Revenues Up

barbara.lempert Amgen’s Second Quarter 2013 Revenues Increased 5 Percent To $ 4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $ 1.89 Second ...

DOJ: Pfizer to Pay $490.9M to Settle Wyeth Rapamune Marketing Case

barbara.lempert Wyeth Pharmaceuticals Agrees to Pay $ 490.9 Million for Marketing the Prescription Drug Rapamune for Unapproved Uses Wyeth Pharmaceuticals Inc., a pharmaceutical ...

BREAKING: Pfizer unit pleads guilty, agrees to pay $491M in off-label marketing case

Tracy Staton According to the Justice Department, Wyeth trained sales reps to push Rapamune for unapproved uses and offered bonuses to persuade them to flog the drug for patients it ...

Pfizer Pays $491M For Illegal Rapamune Marketing That Targeted Blacks

esilverman One of the more sensational whistleblower episodes has finally been resolved now that Pfizer has agreed to pay nearly $ 491 million to settle civil and criminal ...
Page 3 of 6112345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS